Neumora Therapeutics, Inc. (NMRA)
| Market Cap | 331.20M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -293.70M |
| Shares Out | 161.56M |
| EPS (ttm) | -1.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,613,825 |
| Open | 2.190 |
| Previous Close | 2.170 |
| Day's Range | 2.000 - 2.190 |
| 52-Week Range | 1.830 - 21.000 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 20.67 (+908.29%) |
| Earnings Date | Mar 6, 2025 |
About NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NMRA stock is "Strong Buy." The 12-month stock price forecast is $20.67, which is an increase of 908.29% from the latest price.
News
Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA
LOS ANGELES--(BUSINESS WIRE)--Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA.
Neumora's depression drug fails trial, sinking shares
CNBC's Angelica Peebles joins 'Power Lunch' to discuss Neumora's depression drug failing its trial results.
Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals
Neumora Therapeutics (NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a late-stage study of its experimental treatment for depression did not meet i...
Neumora Therapeutics' stock craters after trial of major depressive disorder fails to meet main goals
News is a setback for the clinical-stage biotech and a drug that proved successful in earlier trials
Neumora Therapeutics' depression drug fails to meet main goal of late-stage study
Neumora Therapeutics said on Thursday its experimental drug to treat depression failed to meet the main goal of a late-stage study.
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo
Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck
Neumora Therapeutics is set to release data from the phase 3 KOASTAL-1 study using Navacaprant for the treatment of patients with MDD by the end of 2024; other data in 2025. Navacaprant showed signifi...
This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho
Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for majo...
Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Helen Rubinstein – Vice President of Investor Relations Henry Gosebruch – P...
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025
Neumora Therapeutics to Participate in Upcoming Conferences in November
WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and ...
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation
NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of aggression, stress and anxiety response
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024
Neumora's early-stage schizophrenia drug study put on hold
Neumora Therapeutics said on Monday the U.S. Food and Drug Administration (FDA) had placed a clinical hold on early-stage study of its experimental schizophrenia drug, sending its shares down more tha...
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
WATERTOWN, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and...
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced tha...
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NMRA-266 in healthy adult participants mid-2024
Neumora: Phase 3 MDD Readout In H2-24 Could Get Ball Rolling
Neumora: Phase 3 MDD Readout In H2-24 Could Get Ball Rolling
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the ...
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that...
Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the ...
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia NMRA-266 is a highly selective positive all...
IPO pipeline welcomes some profitable companies, raising hopes for a rebound
The U.S. initial public offering calendar is empty this holiday-shortened week, but some recent additions to the pipeline suggest December could be livelier and welcome deals from some profitable, dec...